,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-10-15 07:35:00,St. Jude Medical Inc. ( STJ ) posted a 7.8% rise in adjusted net earnings per share to 97 cents for the third quarter of 2014 from 90 cents in the year-ago quarter.,0.9578482508659363,0.02381301112473011,0.018338734284043312,positive,0.9340352416038513
1,2014-10-15 07:35:00,"With this, the St. Paul, MN-based medical device maker's earnings per share beat the Zacks Consensus Estimate by a penny and met the upper-end of the company's own guidance range of 95 to 97 cents for the quarter.",0.948047399520874,0.02762962318956852,0.024322956800460815,positive,0.9204177856445312
2,2014-10-15 07:35:00,Net adjusted earnings rose 7.3% to $281 million from $262 million in the 2013-third quarter.,0.9586969614028931,0.023679545149207115,0.017623547464609146,positive,0.9350174069404602
3,2014-10-15 07:35:00,"Reported earnings were $238 million or 82 cents per share in the quarter, down from $262 million or 90 cents per share in the comparable quarter of 2013.",0.016077348962426186,0.9726593494415283,0.011263306252658367,negative,-0.9565820097923279
4,2014-10-15 07:35:00,"Revenues grew 2.5% (both in reported and constant-currency) to $1,372 million for the quarter, lagging the Zacks Consensus Estimate of $1,382 million but lied within the company's own guided range of $1,315 to $1,395 million.",0.957684338092804,0.023027589544653893,0.019288023933768272,positive,0.9346567392349243
5,2014-10-15 07:35:00,"New products such as CardioMEMS heart failure monitoring system contributed to the revenue growth in the quarter, offset by sluggish growth in international markets.",0.9458356499671936,0.027959220111370087,0.026205148547887802,positive,0.9178764224052429
6,2014-10-15 07:35:00,"Revenues from the international market rose 2.0% to $706 million, accounting for 51.5% of total revenues.",0.9533601999282837,0.01783423312008381,0.028805626556277275,positive,0.9355259537696838
7,2014-10-15 07:35:00,"Revenues from the U.S. inched up 3.1% to $666 million, accounting for 48.5% of total revenues.",0.9530874490737915,0.022513380274176598,0.024399129673838615,positive,0.9305740594863892
8,2014-10-15 07:35:00,"In the Cardiac Rhythm Management (CRM) division, revenues inched up roughly 1% (both in reported and constant-currency) to $688 million.",0.9573813676834106,0.018720999360084534,0.023897653445601463,positive,0.9386603832244873
9,2014-10-15 07:35:00,U.S. revenues upped 3.6% to $373 million but international revenues fell 2.2% to $315 million in the quarter.,0.026005418971180916,0.9631104469299316,0.010884164832532406,negative,-0.9371050000190735
10,2014-10-15 07:35:00,"In the CRM division, implantable cardiac defibrillator (ICD) revenues escalated roughly 1% (both in reported and constant-currency) to $422 million.",0.9548651576042175,0.024510521441698074,0.02062433958053589,positive,0.930354654788971
11,2014-10-15 07:35:00,"Meanwhile, pacemaker revenues scaled up roughly 1% (both in reported and constant currency) to $266 million compared with the prior year quarter.",0.9533593654632568,0.02661944180727005,0.020021243020892143,positive,0.9267399311065674
12,2014-10-15 07:35:00,"In the A trial Fibrillation (AF) division, revenues escalated 7.7% (both in reported and constant currency) to $253 million.",0.9573508501052856,0.022917136549949646,0.01973201520740986,positive,0.9344336986541748
13,2014-10-15 07:35:00,International revenues grew 11.5% to $155 million while U.S. revenues rose 2.1% to $98 million in the quarter.,0.9553524851799011,0.020275747403502464,0.02437184937298298,positive,0.9350767135620117
14,2014-10-15 07:35:00,"In the Cardiovascular division, revenues went up 2.2% to $324 million in the quarter (both in reported and constant-currency).",0.9572110176086426,0.02049447037279606,0.022294485941529274,positive,0.9367165565490723
15,2014-10-15 07:35:00,Revenues from the international market stayed nearly flat at $204 million while revenues from the U.S. market rose 5.3% to $120 million.,0.5251832008361816,0.43147018551826477,0.04334663599729538,positive,0.09371301531791687
16,2014-10-15 07:35:00,"In the Cardiovascular division, vascular product revenues edged up roughly 1% to $169 million.",0.9560133814811707,0.020883221179246902,0.023103496059775352,positive,0.9351301789283752
17,2014-10-15 07:35:00,"Meanwhile, structural heart product revenues increased 4% to $155 million for the quarter.",0.9577420949935913,0.017386293038725853,0.024871675297617912,positive,0.9403557777404785
18,2014-10-15 07:35:00,"In the Neuromodulation division, revenues went up 2.9% to $107 million in the third quarter, both on reported and constant-currency bases.",0.957109808921814,0.01961209625005722,0.02327808178961277,positive,0.9374977350234985
19,2014-10-15 07:35:00,Revenues from the U.S. ebbed 1.3% to $75 million but revenues from the international market improved 14.3% to $32 million in the 2014-third quarter.,0.9415048956871033,0.036213185638189316,0.022281939163804054,positive,0.905291736125946
20,2014-10-15 07:35:00,"St. Jude Medical had cash and cash equivalents of $1,294 million as of Sep 27, 2014, down 5.8% from $1,373 million as of Dec 28, 2013.",0.017315233126282692,0.971561074256897,0.011123694479465485,negative,-0.9542458653450012
21,2014-10-15 07:35:00,"Total debt rose 7.9% to $3,864 million as of Sep 27, 2014 compared with $3,580 million as of Dec 28, 2013.",0.9501982927322388,0.024670664221048355,0.025131070986390114,positive,0.9255276322364807
22,2014-10-15 07:35:00,"Consequently, debt-to-capitalization increased 340 basis points to 48.2% from 44.8% as of Dec 28, 2013.",0.9595775604248047,0.02065994031727314,0.01976245827972889,positive,0.9389176368713379
23,2014-10-15 07:35:00,"For the fourth quarter of 2014, St. Jude Medical expects revenues in the range of $1,385 to $1,465 million while the company anticipates adjusted net earnings per share to lie between $1.02 and $1.04 for the quarter.",0.0987325981259346,0.020893050357699394,0.8803743124008179,neutral,0.07783954590559006
24,2014-10-15 07:35:00,"The current Zacks Consensus Estimates for revenues and earnings per share for the quarter are pegged at $1,509 million and $1.05.",0.027870696038007736,0.028216155245900154,0.9439131617546082,neutral,-0.0003454592078924179
25,2014-10-15 07:35:00,"For full year 2014, St. Jude Medical downgraded its revenues guidance to the range of $5,568 to $5,648 million compared with the earlier range of $5,640 to $5,760 million.",0.01913250982761383,0.9572972059249878,0.023570336401462555,negative,-0.9381647109985352
26,2014-10-15 07:35:00,The company has also modified its adjusted earnings per share guidance to the range of $3.97 to $3.99 compared with the earlier range of $3.96 to $4.01.,0.4707687199115753,0.12513282895088196,0.4040985107421875,positive,0.34563589096069336
27,2014-10-15 07:35:00,"The current Zacks Consensus Estimates for revenues and earnings per share for the year are pegged at $3.99 and $5,703 million.",0.025628188624978065,0.02797502651810646,0.9463967084884644,neutral,-0.002346837893128395
28,2014-10-15 07:35:00,We are impressed with St. Jude Medical's third quarter earnings beat but disappointed about the revenue miss.,0.026526669040322304,0.9585580825805664,0.014915307983756065,negative,-0.9320313930511475
29,2014-10-15 07:35:00,"We are optimistic about the company's recent acquisition of privately-held CardioMEMS, Inc. With the closure of the CardioMEMS acquisition, St. Jude Medical expects accelerated growth in its cardiovascular segment.",0.939942479133606,0.014129793271422386,0.04592767357826233,positive,0.9258126616477966
30,2014-10-15 07:35:00,"Further, with the completion of its acquisition of NeuroTherm, Inc., St. Jude Medical is now the only medical device manufacturer with a chronic pain product portfolio that offers both radiofrequency ablation and spinal cord stimulation.",0.6079687476158142,0.009830939583480358,0.38220036029815674,positive,0.5981377959251404
31,2014-10-15 07:35:00,"Currently, St. Jude carries a Zacks Rank #4 (Sell).",0.1986512541770935,0.033674150705337524,0.7676746249198914,neutral,0.16497710347175598
32,2014-10-15 07:35:00,"Some better-ranked stocks in the medical products industry include ZELTIQ Aesthetics, Inc. ( ZLTQ ), Abaxis, Inc. ( ABAX ), and Alere Inc. ( ALR ).",0.7151417136192322,0.02652774378657341,0.2583305835723877,positive,0.6886139512062073
33,2014-10-15 07:35:00,"ZELTIQ Aesthetics sport a Zacks Rank #1 (Strong Buy), while both Abaxis and Alere carry a Zacks Rank #2 (Buy).",0.47239425778388977,0.024933740496635437,0.502672016620636,neutral,0.4474605321884155
34,2014-10-15 07:35:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
35,2014-10-15 07:35:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069374665617943,0.007019795011729002,0.9422864317893982,neutral,0.04367395117878914
36,2014-10-15 07:35:00,"Click to get this free report

To read this article on Zacks.com click here.",0.02068457007408142,0.033159855753183365,0.9461556077003479,neutral,-0.012475285679101944
37,2014-10-15 07:35:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
